Lucy Colson is an independent advisor to startup founders, helping them raise, scale and exit. She has worked with 250+ startups, supported a £3m seed round and an acquisition.
She works directly with leadership teams to develop the winning strategy and build the team, culture, processes and evidence investors and acquirers expect. The result: stronger raises, faster scaling that doesn’t depend on the founding team, and cleaner, more valuable exits.
Build the evidence, strategy, economics, operating credibility and fast-rolling process that close your round faster.
10x your revenue with operations that don’t depend on the founding team
Build a less founder-dependent, more transferable company with a higher valuation.
Every stage of raising, scaling and exiting has different needs. Choose the engagement that matches where the company is today.
Acquisition, conversion, retention, pipeline, positioning, customer evidence and repeatable commercial execution.
Scale objectives, strategic choices, milestones, resource allocation and initiative sequencing.
Less founder dependence, stronger leadership resilience, knowledge transfer, delegation and reduced routine escalation.
Roles, accountability, decision rights, management capability, hiring, workload and cross functional coordination.
Processes, SOPs, reporting, meeting cadence, management information, onboarding and continuous improvement.
People, spend, systems and initiatives assessed against the value and leverage they create.
Workflow redesign, automation and AI adoption where the business case is clear and the process is ready.
Clearer strategy, priorities, operating evidence and progress for people responsible for governing or financing the company.
See how founders across every stage turn structure into measurable, fundable momentum.

A pre-raise retainer built the multi-persona buyer journey and sales playbooks that carried C U Health to a £3 million seed round.

Lucy started her first business at 20 (solo, no advisors, no safety net) and learned the hard way what kills early-stage companies: not effort, but unfocused execution against a ticking runway. Since 2021 she's worked with 250+ startups across the UK, US, EU, Middle East and Australia, helped a B2B health-tech company close a £3M seed round, and supported a successful acquisition.
LinkedIn ↗Operating Partners and board members refer portfolio founders when execution, not strategy, is the risk to the outcome. They want stronger operating discipline, more reliable growth and fewer opaque execution risks.
Tell us a bit about what you need, and we'll be in touch.